Artio closes $28M as it scales to save lives; latest funding brings Prairie Village startup’s investments to $74M
June 16, 2022 | Startland News Staff
Another hefty funding round for Artio Medical is expected to launch the startup’s commercial sales team in the U.S. and continue development of its best-in-class product pipeline, said founder Nicholas Franano.
Artio, a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, on Thursday announced the closing of $28 million in oversubscribed Series A2 and Series A3 financing, bringing the total amount raised to date to $74 million.
Funds will be used to support U.S. commercialization efforts for the recently cleared Solus Gold Embolization Device and to accelerate the development of Artio’s broad portfolio of products, including expanding the company’s engineering and manufacturing capabilities, Franano said in a press release.
Click here to read more about Artio’s $12 million funding infusion in 2021.
“We would like to thank our existing investors for their continued strong support and also welcome a new group of investors to Artio,” said Joseph McConnell, vice president of finance and business operations at Artio.
“We have the opportunity to do something really special here, to bring a new generation of medical devices to market with the potential to save lives, reduce disability, and improve the quality of life for millions of people,” McConnell continued. “This new capital will help Artio expand our team and scale our operations to deliver on that mission.”
Artio is currently developing ten products for the peripheral vascular market, including the Solus Gold and Solus Flex Embolization Devices for peripheral vessel occlusion and the Amplifi Vein Dilation System which is designed to prepare hemodialysis patients for successful arteriovenous fistula vascular access site creation.
Artio is also currently developing four products for the neurovascular market, including the Endura Embolization System comprising a detachable balloon and coils for the treatment of saccular brain aneurysms.
Click here to learn more about Artio’s portfolio of products.

2022 Startups to Watch
stats here
Related Posts on Startland News
How this Andre’s Valentine collaboration celebrates the friendship that sparked Kate Spade
The favorite hometown chocolate of one Kansas City’s best-known fashion designers and entrepreneurs serves as just one ingredient in a new Valentine’s Day collaboration from André’s Confiserie Suisse. The local chocolatier just rolled out a limited edition line alongside Frances Valentine to mark the holiday, as well as celebrate the friendship between Elyce Arons and…
Electric Americana: How singer Teri Quinn broke from the pack (and found her own in KC)
Members of the Kansas City-based band Teri Quinn & The Coyotes are carving a distinctive space within the local music scene. From Appalachian banjo riffs to punk-inspired beats, their sound reflects diverse influences — howling loudest from the woman in front. Attendees at Startland News’ Jan. 23 reception for the Kansas City Startups to Watch…
C2FO hits its first billion-dollar day; marks $400B in funding to customers as global finance shifts
A record-breaking year for C2FO serves as a proof point itself, said Sandy Kemper, revealing the Kansas City-built fintech surpassed $400 billion in lifetime funding to its customers in 2024 and achieved $1 billion of daily funding for the first time. “The success of the past year only demonstrates the tremendous need for more efficient…
KC Biohub leader bullish on Tech Hubs funding after region missing from latest grants list
Kansas City is still in the running for a chunk of the remaining $280 million in expected funding for federal Tech Hubs implementation grants, said Melissa Roberts Chapman, emphasizing the region remains primed and competitive in the process despite the KC BioHub not being among the latest awardees announced by the program. Six other projects…

